Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics. Avacta said it may receive. Background: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. He had also worked as a senior executive at Bristol Myers Squibb. As a proven platform technology addressing multiple non-therapeutic markets the Group has the opportunity to establish a profitable reagents business, and there is significant upside potential as it builds a pipeline of valuable Affimer drug assets. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. We have developed Affimer technology, an engineered alternative to antibodies.
Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Dr Jose Saro appointed as Chief Medical Officer to oversee translation of pre-clinical programmes into the clinic. · Strong focus on generating further license deals during 2019 arising from multiple ongoing technology evaluations. This combination of the growing technical and commercial progress is expected to help catalyse further significant partnerships in due course. Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Losses were also exacerbated by administrative expenses increasing by 3% to £4.
The addition of Dr Jose Saro as Chief Medical Officer is a significant strengthening of the senior management team with regards this translation of programmes into the clinic. To register for news alerts by email go to www. Following this update there will also be an opportunity to speak with other members of the senior management. The addition of Dr Jose Saro as Chief Medical Officer is a significant strengthening of the senior management team with regards this translation of programmes into the clinic. The Group will develop some of these Affimer assets to the point of having working assays with data that clearly differentiates them from the current diagnostic products in the market.
This agreement is to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays. Whilst the lead programmes progress into the clinic, the Group will continue to build-out its pipeline of immuno-oncology assets. The developer of Affimer biotherapeutics and research reagents said operating losses rose to £3. The Life Sciences segment offers custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development. Half year revenues increased 16% to £1. Dr Eliot Forster Dr Alastair Smith Chairman Chief Executive Officer 9 April 2019 9 April 2019 Condensed consolidated income statement for the six-month period ended 31 January 2019 Unaudited Unaudited Audited 6 months to 31 January 2019 6 months to 31 January 2018 Year ended 31 July 2018 £000 £000 £000 Revenue 972 1,466 2,763 Cost of sales 308 458 893 Gross profit 664 1,008 1,870 Research and development costs 2,414 1,477 3,783 Administrative expenses 4,122 4,003 8,518 Operating loss 5,872 4,472 10,431 Finance income 23 23 41 Loss before taxation 5,849 4,449 10,390 Taxation 650 500 1,561 Loss and total comprehensive loss for the period attributable to equity shareholders 5,199 3,949 8,829 Loss per ordinary share: - Basic and diluted 4.
Group chief executive Dr Alastair Smith said: 'The. The interim financial information for the six months ended 31 January 2019 and the comparative financial information for the six months ended 31 January 2018 are unaudited. Whilst the lead programmes progress into the clinic, the Group will continue to build-out its pipeline of immuno-oncology assets. The Group remains on track, to a tight schedule, to dose first patients in late 2020. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
The group said the evening event - which would begin with registration at 17:30 - would provide an opportunity for investors to hear about the company's Affimer technology, its development plans and discuss these with Smith, chief commercial officer and chairman Philippe Cotrel. Dr Saro joined Avacta from Roche where he held the role of Senior Translational Medicine Leader at the Roche Innovation Center Zurich. The group said this provided an opportunity for investors to hear about the company's Affimer technology, its development plans and to meet with management. It said work carried out collaboratively between Avacta and Covance. First-time-in-human data is a significant value inflection point for the technology and a major de-risking point from a deal making perspective.
Avacta is targeting long-term, significant value generation through in-house and partnered Affimer therapeutic development programmes. The event begins at 18:00. To register for news alerts by email go to www. The value of investments and any income from them, can fall as well as rise so you could get back less than you invest. If in any doubt, please seek advice. Avacta said the new conjugate would selectively release a potent drug in the tumour.
Avacta will generate and carry out early-stage optimisation of Affimer drug candidates against multiple undisclosed targets. Affimers represent a radical alternative to established antibody technology which dominates the. It said counterparts to this patent had already been. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. This combination of the growing technical and commercial progress is expected to help catalyse further significant partnerships in due course. Avacta said it was developing a single-molecule bi-specific therapy with a view to entering phase I clinical development in 2020. Avacta says Evan brings world-leading expertise in immuno-oncology and cancer stem cell research to support the froup's development of oncology biotherapeutics based on its proprietary Affimer technology.